ReviewCureus2025
A Systematic Review of the Diagnostic Role of BRAF V600E Testing in Thyroid Nodules with Atypia of Undetermined Significance.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BRAF V600E mutation is a key molecular marker for malignancy in thyroid nodules showing cytological features of atypia of undetermined significance (AUS). It is strongly associated with papillary thyroid carcinoma (PTC), improves diagnostic accuracy and clinical management stratification, and serves as a significant risk factor of malignancy (ROM) when combined with identifying aggressive features such as lymph node metastases and extra-thyroid extension. This systematic literature review examines the diagnostic role of the BRAF V600E mutation in AUS nodules, emphasizing its integration with cytological evaluation, ultrasound-based risk stratification systems (US-RSS), and cytological subclassification. Selective BRAF testing improves sensitivity and specificity, optimizing resource utilization while reducing unnecessary surgeries. Incorporation of this mutation into multigene classifiers, such as ThyroSeq v3, further supports cost-effective and personalized management strategies for indeterminate thyroid nodules. By combining molecular and imaging data, BRAF V600E testing plays a pivotal role in advancing thyroid cancer diagnosis and treatment. It enhances malignancy risk stratification and facilitates precise clinical decision-making, leading to improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.